An interventional study of Exercise intervention and Usual care in Inflammatory Bowel Diseases, sponsored by Rijnstate Hospital. Completed at 4 sites in Netherlands. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Rijnstate Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Inflammatory Bowel Diseases with a site in Netherlands — 22 open to participants now, 28 under way, 7 of them phase 3. Inflammatory Bowel Diseases · Netherlands.
Among the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands, this one is the 32nd largest by enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2023, is one of 16 with no phase, and was the 58th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →22 of the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands are open now. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18–75
Radboud University Medical Center · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 19 · Phase 3 19 · Phase 4 9
First in 2005; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 120 across the 61 interventional studies, 378 across the 18 observational. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 79 have an industry lead sponsor. The 10 most frequent:
Rijnstate Hospital is the lead sponsor of 130 studies on the registry; 13 are open to participants now.
Rijnstate Hospital has 2 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
5 of the studies in Inflammatory Bowel Diseases with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07582458Phase 3Radboud University Medical CenterModafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) | 2027-02-01 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT06723418University of GlasgowDevelopment and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS) | 2026-12 |
| NCT06179563Franciscus GasthuisTOD-IBD: Empowering Patients On-Demand | 2027-07-01 |
| NCT05659953Lmito Therapeutics Inc.LMT503 First-in-human SAD, MAD, and FE Study | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In patients with inflammatory bowel diseases (IBD), characterized by relapsing intestinal inflammation, chronic fatigue is a burdensome and highly prevalent symptom. The aetiology is thought to be multifactorial, including complex interactions of psychological and physical factors such as immunological profiles and gut microbiota. Unfortunately, specific treatment strategies are currently lacking. Since fatigued patients have an impaired physical fitness and are less physically active than patients without fatigue, it is hypothesised that physical exercise might be an effective complementary treatment for patients with IBD suffering from fatigue. During a previous pilot cohort study, significant improvements in fatigue complaints and quality of life were observed following a personalised and intensive exercise program. In this study, a multicenter randomized controlled trial will be performed to further investigate this assumed beneficial effect of intensive physical exercise.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Comorbidities that prevent safe participation in the exercise program/cardiorespiratory fitness test including;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patients in the intervention group will follow a personalised and intensive exercise program.
Behavioral: Exercise intervention
The patients in the control group will receive usual care.
Other: Usual care
A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.
Usual care, including general advice concerning chronic fatigue.
Change in fatigue (IBD-F), post-intervention
Mean change in fatigue, measured with the inflammatory bowel disease fatigue self-assessment scale (IBD-F) 0-140 with higher scores indicating worse fatigue, in the intervention group compared to the control group.
Time frame: 3 months (post-intervention)
Change in quality of life (IBDQ), post-intervention
Mean change in quality of life, measured with the inflammatory bowel disease questionnaire (IBDQ) 32-224 with higher scores representing better quality of life, in the intervention group compared to the control group.
Time frame: 3 months (post-intervention)
Long-term change in fatigue (IBD-F)
Mean change in fatigue, as measured after 6- and 12-months using the IBD-F, in the intervention group compared to the control group
Time frame: 6- and 12-months
Long-term change in quality of life (IBDQ)
Mean change in quality of life, as measured after 6- and 12-months using the IBDQ, in the intervention group compared to the control group
Time frame: 6- and 12-months
Change in cardiorespiratory fitness (maximum oxygen uptake)
Change in cardiorespiratory fitness (maximum oxygen uptake) of patients in the intervention group, assessed using Cardiopulmonary Exercise Testing (CPET).
Time frame: 3 months (post-intervention)
Change in cardiorespiratory fitness (maximum power)
Change in cardiorespiratory fitness (maximum power) of patients in the intervention group, assessed using Cardiopulmonary Exercise Testing (CPET).
Time frame: 3 months (post-intervention)
Change in muscular strength
Change in muscular strength of patients in the intervention group, assessed using one-repetition maximum (1-RM)
Time frame: 3 months (post-intervention)
Change in body composition (BMI)
Change in body composition in the intervention group, as determined by body mass index (BMI).
Time frame: 3 months (post-intervention)
Change in body composition (body fat percentage)
Change in body composition in the intervention group, as determined by body fat percentage measured using skinfold techniques
Time frame: 3 months (post-intervention)
Change in work absenteeism and presenteeism
Change in work absenteeism and presenteeism in the intervention group compared to the control group, as measured by the Productivity Cost Questionnaire (iPCQ)
Time frame: T= 3-, 6-, 9-, and 12-months
Disease activity (FCP)
Disease activity measured by change in faecal calprotectin (FCP), in both the intervention- and control group
Time frame: T= 3-, 6-, 9-, and 12-months
Disease activity (step-up therapy)
Disease activity measured by step-up therapy rate in both the intervention- and control group
Time frame: T= 3-, 6-, 9-, and 12-months
Disease activity (exacerbation rate)
Disease activity measured by exacerbation rate in both the intervention- and control group
Time frame: T= 3-, 6-, 9-, and 12-months
Change in sleep quality
Self-reported differences in sleep quality in the intervention group compared to the control group, using the Pittsburgh Sleep Quality Index (PSQI), 0-21 with higher scores indicating worse sleep quality.
Time frame: T= 3-, 6-, 9-, and 12-months
Change in anxiety and depression symptoms
Mean change in anxiety and depression symptoms in the intervention group compared to the control group, measured using the Hospital Anxiety and Depression Scale (HADS) questionnaire, each subscale 0-21 higher scores indicating worse symptoms
Time frame: T= 3-, 6-, 9-, and 12-months
Targeted cost-utility analysis
Targeted economic evaluation of the intervention using a targeted cost-utility analysis from a societal perspective including intervention costs, medical consumption costs and productivity loss. Effectiveness of the intervention will be determined using the mean Difference of quality adjusted life years (QALYs) between de intervention and control group, based on the designated EQ-5D-5L questionnaire.
Time frame: 12 months
Exploratory outcome measurements (immunological profiles)
Differences in the immunological profiles (i.e. pro- and anti-inflammatory cytokines and soluble receptors, such as IL-10, IL-6, IFN-ɣ) in the intervention group compared to the control group
Time frame: 3 months (post-intervention)
Exploratory outcome measurements (gut microbiota)
Differences in the gut microbiota diversity and composition in the intervention group compared to the control group using 16SrRNA sequencing.
Time frame: 3 months (post-intervention)
Exploratory outcome measurements (biogenic amines)
Differences in the concentration of biogenic amines in the intervention group compared to the control group.
Time frame: 3 months (post-intervention)
Plan to share: No
Ran from Jan 2023 to primary completion in Jul 2025, 29 months.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 29 months is close to that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2024 → Jul 2025 and completion Dec 2025 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.